Cover Image

IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression

Aryl hydrocarbon receptor (AHR) activation by tryptophan (Trp) catabolites enhances tumor malignancy and suppresses anti-tumor immunity. The context specificity of AHR target genes has so far impeded systematic investigation of AHR activity and its upstream enzymes across human cancers. A pan-tissue...

Full description

Saved in:
Bibliographic Details
Main Authors: Sadik, Ahmed (Author) , Somarribas Patterson, Luis F. (Author) , Öztürk, Selcen (Author) , Mohapatra, Soumya R. (Author) , Panitz, Verena (Author) , Secker, Philipp F. (Author) , Holfelder, Pauline (Author) , Loth, Stefanie (Author) , Salem, Heba (Author) , Prentzell, Mirja Tamara (Author) , Berdel, Bianca (Author) , Iskar, Murat (Author) , Faessler, Erik (Author) , Reuter, Friederike (Author) , Kirst, Isabelle (Author) , Kalter, Verena (Author) , Foerster, Kathrin (Author) , Jäger, Evelyn (Author) , Guevara, Carina Ramallo (Author) , Sobeh, Mansour (Author) , Hielscher, Thomas (Author) , Poschet, Gernot (Author) , Reinhardt, Annekathrin (Author) , Hassel, Jessica C. (Author) , Zapatka, Marc (Author) , Hahn, Udo (Author) , Deimling, Andreas von (Author) , Hopf, Carsten (Author) , Schlichting, Rita (Author) , Escher, Beate I. (Author) , Burhenne, Jürgen (Author) , Haefeli, Walter E. (Author) , Ishaque, Naveed (Author) , Böhme, Alexander (Author) , Schäuble, Sascha (Author) , Thedieck, Kathrin (Author) , Trump, Saskia (Author) , Seiffert, Martina (Author) , Opitz, Christiane (Author)
Format: Article (Journal)
Language:English
Published: August 19, 2020
In: Cell
Year: 2020, Volume: 182, Issue: 5, Pages: 1252-1270.e34
ISSN:1097-4172
DOI:10.1016/j.cell.2020.07.038
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.cell.2020.07.038
Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0092867420309466
Get full text
Author Notes:Ahmed Sadik, Luis F. Somarribas Patterson, Selcen Öztürk, Soumya R. Mohapatra, Verena Panitz, Philipp F. Secker, Pauline Pfänder, Stefanie Loth, Heba Salem, Mirja Tamara Prentzell, Bianca Berdel, Murat Iskar, Erik Faessler, Friederike Reuter, Isabelle Kirst, Verena Kalter, Kathrin I. Foerster, Evelyn Jäger, Carina Ramallo Guevara, Mansour Sobeh, Thomas Hielscher, Gernot Poschet, Annekathrin Reinhardt, Jessica C. Hassel, Marc Zapatka, Udo Hahn, Andreas von Deimling, Carsten Hopf, Rita Schlichting, Beate I. Escher, Jürgen Burhenne, Walter E. Haefeli, Naveed Ishaque, Alexander Böhme, Sascha Schäuble, Kathrin Thedieck, Saskia Trump, Martina Seiffert, and Christiane A. Opitz
Description
Summary:Aryl hydrocarbon receptor (AHR) activation by tryptophan (Trp) catabolites enhances tumor malignancy and suppresses anti-tumor immunity. The context specificity of AHR target genes has so far impeded systematic investigation of AHR activity and its upstream enzymes across human cancers. A pan-tissue AHR signature, derived by natural language processing, revealed that across 32 tumor entities, interleukin-4-induced-1 (IL4I1) associates more frequently with AHR activity than IDO1 or TDO2, hitherto recognized as the main Trp-catabolic enzymes. IL4I1 activates the AHR through the generation of indole metabolites and kynurenic acid. It associates with reduced survival in glioma patients, promotes cancer cell motility, and suppresses adaptive immunity, thereby enhancing the progression of chronic lymphocytic leukemia (CLL) in mice. Immune checkpoint blockade (ICB) induces IDO1 and IL4I1. As IDO1 inhibitors do not block IL4I1, IL4I1 may explain the failure of clinical studies combining ICB with IDO1 inhibition. Taken together, IL4I1 blockade opens new avenues for cancer therapy.
Item Description:Gesehen am 21.08.2020
Physical Description:Online Resource
ISSN:1097-4172
DOI:10.1016/j.cell.2020.07.038

Similar Items